Safety and Preliminary Efficacy Assessment of AZD7789 in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Exclusion Criteria

• • Unresolved toxicities of ≥ Grade 2 from prior therapy
• • Any prior ≥ Grade 3 imAE while receiving prior checkpoint inhibitor immunotherapy
• • Patients with central nervous system (CNS) involvement or leptomeningeal disease.
• • History of allogeneic stem cell transplant or organ transplantation.
• • Any venous or arterial thromboembolic event within ≤ 6 months prior to the first dose of study intervention.
• • Active infection including Tuberculosis (TB), human immunodeficiency virus (HIV), hepatitis A, chronic or active hepatitis B, chronic or active hepatitis C, active COVID-19 infection
• • History of arrhythmia which is requires treatment, symptomatic or uncontrol led atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia
• • Uncontrolled intercurrent illness.
• • Active or prior documented pathologically confirmed autoimmune or inflammatory disorders.
• • Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD
• • Other invasive malignancy within 2 years prior to screening
• • Congenital long QT syndrome or history of QT prolongation associated with other medications that cannot be changed or discontinued based on a cardiologist assessment
• • Current or prior use of immunosuppressive medication within 14 days prior to the first dose of study intervention
• • Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.